Vaccine

Abstract

The invention relates to a replication deficient simian adenoviral vector C7 encoding a protein comprising CS protein from P. falciparum or a fragment thereof, for example as shown in Seq ID No: 1 or Seq ID No: 3. The invention also relates to processes of preparing said viral vector and use of the viral vector in the treatment/prevention of malaria infection. Compositions, vaccines and kits comprising said viral vector are also described. In one aspect the invention employs a synthetic C7 viral vector. The C7 viral vector according to the invention may be co-administered or co-formulated with a malaria antigen such as RTS,S optionally in the presence of an adjuvant for example comprising 3D-MPL and/or a saponin such as QS21.

1 . A replication deficient simian adenoviral vector C7 encoding a protein comprising CS protein from  P. falciparum  or an immunogenic fragment thereof. 
     
     
         2 . The adenoviral vector of  claim 1 , wherein the protein encoded comprises the sequence of Seq ID No: 7. 
     
     
         3 . The adenoviral vector of  claim 1 , where the encoded protein encoded comprises the sequence of Seq ID No: 8. 
     
     
         4 . The adenoviral vector any one of  claim 1 , wherein the encoded protein has the sequence of Seq ID No: 1. 
     
     
         5 . The adenoviral vector of  claim 1 , wherein the encoded protein has the sequence of Seq ID No: 3. 
     
     
         6 . A pharmaceutical composition comprising the adenoviral vector of  claim 1  and an excipient. 
     
     
         7 . An immunogenic composition for the treatment or prophylaxis of malaria comprising the adenoviral vector of  claim 1  and an adjuvant. 
     
     
         8 . The immunogenic composition of  claim 7 , which further comprises a protein. 
     
     
         9 . The immunogenic composition of  claim 8 , wherein the protein is RTS,S. 
     
     
         10 . An immunogenic composition comprising
 (1) a replication deficient simian adenoviral vector C7 encoding a protein comprising CS protein from  P. falciparum  or an immunogenic fragment thereof,   (2) a malaria antigen, and   (3) an adjuvant.   
     
     
         11 . A kit comprising
 (1) a replication deficient simian adenoviral vector C7 encoding a protein comprising CS protein from  P. falciparum  or an immunogenic fragment thereof,   (2) a malaria antigen, and   (3) an adjuvant.   
     
     
         12 . The immunogenic composition of  claim 10 , wherein the protein encoded by the adenoviral vector C7 has the sequence of Seq ID No: 1. 
     
     
         13 . The immunogenic composition of  claim 10 , wherein the malaria antigen is RTS,S. 
     
     
         14 . The immunogenic composition of  claim 10 , wherein the adjuvant comprises 3D-MPL. 
     
     
         15 . The immunogenic composition of  claim 10 , wherein the adjuvant comprises a saponin. 
     
     
         16 . The immunogenic composition of  claim 15 , wherein the saponin is QS21. 
     
     
         17 . The immunogenic composition of  claim 10 , wherein the adjuvant comprises 3D-MPL and QS21. 
     
     
         18 . The immunogenic composition of  claim 10 , wherein the composition is an oil-in-water emulsion. 
     
     
         19 . The immunogenic composition of  claim 10 , wherein the composition is a liposomal formulation. 
     
     
         20 . The immunogenic composition of  claim 10  comprising
 (1) a replication deficient simian adenoviral vector C7 encoding a protein comprising CS protein from  P. falciparum  having the sequence of Seq ID No: 1,   (2) malaria antigen RTS,S, and   (3) an adjuvant comprising 3D-MPL and QS21.   
     
     
         21 . A process for the preparation of a the adenoviral vector of  claim 1  comprising the steps of:
 a. propagating the adenoviral vector on a suitable cell line, and   b. recovering the adenoviral vector.   
     
     
         22 . A process for the preparation of a composition of the immunogenic composition of  claim 10  comprising the step of admixing the adenoviral vector of  claim 1  with at least one excipient/carrier. 
     
     
         23 . (canceled) 
     
     
         24 . (canceled) 
     
     
         25 . (canceled) 
     
     
         26 . A method of treatment or prophylaxis of malaria in a subject comprising administering to a subject in need thereof a therapeutically effective amount of the immunogenic composition of  claim 10 . 
     
     
         27 . A method for the treatment or prophylaxis of malaria in a subject comprising administering to a subject in need thereof a therapeutically effective amount of the adenoviral vector of  claim 1 . 
     
     
         28 . The method of  claim 27 , wherein the adenoviral vector is administered to the subject in a prime-boost regime.